ClinicalTrials.gg
Active, not recruitingNCT06245616CORDIALUpdated Nov 18, 2026

Attenuation of Postprandial Inflammatory Processes in Alzheimer's Disease Patients by Consumption of Pomace Oil

An interventional study of Consumption of olive pomace olive oil by alzheimer's patients and Consumption of high-oleic sunflower oil by alzheimer's patients in Alzheimer's Disease, sponsored by Spanish National Research Council. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Spanish National Research Council · Not applicable, Interventional, and Prevention

How we know

Updated Nov 18, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Alzheimer Disease with a site in Spain — 54 open to participants now, 80 under way, 24 of them phase 3. Alzheimer Disease · Spain.

Planned enrollment
189th of 240
80 · median 258
Started
2024
with 19 others
No phase
66 of 279
17 open now
Primary completion
2026-12
later than 24 of 79 live
Registered
218th of 279
by date

Among the 279 studies in Alzheimer Disease with a site in Spain, this one is the 189th largest by planned enrollment of the 240 interventional ones that give a count, is one of 20 that started in 2024, is one of 66 with no phase, reaches primary completion later than 24 of the 79 other live ones, and was the 218th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

54 of the 279 studies in Alzheimer Disease with a site in Spain are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Alzheimer Disease with a site in Spain, or all of them as a file.
02

Study summary

This research project is based on previous studies suggesting that certain components of olive pomace oil can reduce inflammation in the brain associated with neurodegenerative diseases like Alzheimer\'s. The current hypothesis proposes that particles carrying dietary fats can trigger inflammation, but if they contain bioactive compounds from olive pomace oil, this inflammatory activity will be reduced.

The study aims to recruit 40 adult volunteers, both men and women, diagnosed with early-stage Alzheimer\'s. Participants will be divided into two groups based on their blood triglyceride levels. Additionally, 40 healthy individuals with similar ages will be recruited and divided into two groups based on their triglyceride levels.

Recruitment will take place at the Neurology Department of Virgen de Valme University Hospital in Dos Hermanas, Sevilla. Participants must have a mild stage of Alzheimer\'s, allowing intervention through diet for prevention or slowing down disease progression. Inclusion criteria include good visual and auditory capabilities, disease monitoring by healthcare professionals, and voluntary written consent approved by the hospital\'s ethics committee.

Exclusion criteria involve current medical conditions, medication use (except contraceptives), pregnancy or lactation, systemic diseases, cardiovascular events in the last two years, uncontrolled hypertension in the last six months, cancer in the last five years, recent participation in clinical trials, physical or intellectual limitations, and any connection with the study staff.

Participation is voluntary, and participants can withdraw at any time without consequences. The study could benefit Alzheimer\'s patients by reducing brain inflammation and oxidative stress. For healthcare institutions, it may improve care quality and contribute to prevention and treatment policies. Scientifically, it could provide insights into the effects of compounds on Alzheimer\'s patients, potentially leading to new treatment strategies. Olive pomace oil producers may benefit from supporting the oil\'s marketing and usage with health-related information. Overall, the project aims to impact society positively by enhancing disease prevention and treatment.

Regarding risks, the study involves minimal blood extraction, posing no significant threat. Participants may experience slight discomfort due to the catheter during the six-hour study period. Follow-up contact may be necessary, but participants have the right to refuse.

The study will take place at Virgen de Valme University Hospital (Seville), ensuring immediate attention in case of unexpected issues. A qualified nurse, supervised by a doctor, will conduct the procedures. The study is covered by liability insurance to compensate for any health-related issues or injuries during participation.

Two postprandial experiments will be conducted, administering olive pomace oil in one and high-oleic sunflower oil in the other. Blood extractions will occur before and hourly for six hours after participants consume a meal containing the respective oils, accompanied by bread and milk. The food poses no health risks. The blood extraction process involves a simple puncture with inherent risks of any standard blood withdrawal procedure.

The participant has the right to clarify any doubts he/she may have at any time and to request more detailed information about the research. To do so, the participant can contact the researchers, whose contact details are at the beginning of this document.

If the participant considers that all doubts have been clarified and that he/she is convinced that the he/she wants to participate in this study, he/she can then sign the informed consent form.

Read the detailed description
  1. BACKGROUND

    Alzheimer's disease (AD) is the most common cause of dementia and its prevalence is expected to quadruple by 2050. Alzheimer's is characterised pathologically by substantial neuronal loss and chronic inflammation, which is associated with cerebrovascular and parenchymal accumulation of protein deposits enriched in amyloid-beta (Aβ) and hyperphosphorylated Tau protein. Accumulating evidence suggests that disruption of the blood-brain barrier function, which separates the central nervous system from the peripheral circulation, may increase the risk of the onset and worsen the course of AD.

    Microglia have been proposed to play a crucial role in most neuropathologies, as they are activated upon detection of alterations in brain homeostasis. This cell type acts like resident macrophages in the brain, constantly scanning the local microenvironment for signs of infection and injury and becoming activated when found. As a result, a host of pro-inflammatory mediators are released, including cytokines, reactive oxygen species (ROS) and nitric oxide. In contrast, antioxidant defence systems, such as glutathione peroxidase-1 and superoxide dismutase-1, are decreased in AD patients.

    A significant part of plasma Aβ is associated with triglyceride-rich lipoproteins (TRL) that are secreted from hepatocytes and enterocytes. These particles are characterised by apolipoprotein B, which serves as an indicator of postprandial dyslipidaemia, which is an exaggerated but transient increase in TRL after dietary fat absorption and leads to the formation of atherosclerosis. This phenomenon could be the link between cardiovascular disease and Alzheimer's disease. The existence of such a link has already been demonstrated in clinical and cross-sectional studies, but the underlying mechanism remains unclear.

    There is accumulating evidence that dietary fat intake is associated with the onset and progression of Alzheimer's disease. Thus, saturated fatty acid (SFA) intake would be a deleterious factor, promoting dyslipidaemia, endothelial dysfunction, inflammation and oxidative stress. In contrast, consumption of fats rich in poly- or monounsaturated fatty acids (PUFA and MUFA) are associated with lower disease prevalence, probably as a consequence of lower levels of systemic inflammation.

    Olive pomace oil is obtained from the solid by-product of olive oil production by solvent extraction or centrifugation. The storage period of this by-product allows the enrichment of the oil with the components of the fruit peel and tree leaves, of great interest due to their biological activity, which are found only in traces in virgin olive oil. Thus, centrifuged olive pomace oil is enriched in components of the unsaponifiable fraction that are fat-soluble. Although a part of these compounds is lost during refining, under mild refining conditions they can be retained in relevant concentrations. These components include sterols and tocopherols, as well as the triterpenic acids oleanolic and maslinic.

    In previous in vitro studies the investigators demonstrated that the bioactive compounds in olive pomace oil alpha-tocopherol, oleanolic acid and beta-sitosterol were able to attenuate microglial activation, both in isolation and as part of artificial triglyceride-rich lipoproteins (TRL). Microglial attenuation was determined by measuring various markers of inflammation and oxidative stress, which are released by the cell when subjected to stimulation that leads to over-activation. This finding opened the door to the possibility that, if these bioactive compounds reach the brain, they may help prevent or slow down the development of neurodegenerative diseases such as Alzheimer's disease.

    The investigators then conducted a comparative postprandial study to determine whether human TRL obtained after olive pomace oil intake were able to attenuate microglial activation to a greater extent than those obtained after high-oleic sunflower oil intake. The investigators found that at certain times during the postprandial period, the release of markers of inflammation and oxidative stress by microglial cells treated with TRL was lower when they were derived from olive pomace oil intake. Thus, it was demonstrated that, in healthy subjects, consumption of pomace oil during the postprandial period results in the production of lipoproteins carrying its bioactive compounds and that these participate in the attenuation of microglial activation.

    Consequently, the investigators believe that the time has come to test our hypothesis in patients diagnosed with Alzheimer's disease, who present memory problems or incipient cognitive impairment. For this project, the investigators hypothesise that these patients will have alterations in postprandial lipid metabolism that will result in TRL with a greater capacity to over-activate microglia but that the intake of pomace oil will attenuate this activation. If this is the case, it would suggest that the intake of pomace oil may prevent neuroinflammation caused by microglia overactivation, reducing the risk of developing and progressing Alzheimer's disease.

  2. WORKING HYPOTHESIS

    This project is based on the demonstration that TRL, both artificial and of human origin, are capable of eliciting the activation of microglia, a phenomenon associated with neurodegenerative diseases such as Alzheimer\'s disease. In addition, the consumption of olive pomace oil and its bioactive compounds has been shown to be able to attenuate this activation. The approach of this research project is that the consumption of olive pomace oil by alzheimer's patients will lead to the formation of postprandial TRL that maintain these bioactive compounds and thus retain their protective capacity against microglial activation and inflammation.

    If this is the case, the evidence obtained would lay the foundations for the development of new health applications of pomace oil, which would be based on the influence of TRL formed in the postprandial period and which could be used for the prevention and treatment of Alzheimer\'s disease.

  3. OBJECTIVES

To test the above hypothesis, these specific objectives will be addressed:

  1. To determine possible alterations in postprandial lipid metabolism in patients with mild or early stage diagnosed Alzheimer\'s disease.
  2. To assess whether the intake of pomace oil is capable of normalising these alterations in postprandial lipid metabolism in comparison with high-oleic sunflower oil.
  3. To obtain and characterise human TRL obtained after the ingestion of pomace oil or high-oleic sunflower oil.
  4. To evaluate the attenuating effect of microglial activation by TRL obtained after ingestion of pomace oil compared to high-oleic sunflower oil.

4. EXPERIMENTAL DESIGN AND ACTIVITIES

The study is designed as a randomised, double-blind, postprandial crossover trial in Alzheimer\'s patients, who will be divided randomly into two groups and will be compared with healthy controls of the same age. All subjects will receive pomace oil and a high-oleic sunflower oil.

ACTIVITY 1. OBTAINING A POMACE OIL RICH IN BIOACTIVE COMPOUNDS

The olive pomace oil will be provided by ORIVA, while the high oleic sunflower oil will be of commercial origin. Both oils will be characterised at Instituto de la Grasa-CSIC to determine their content in acid and triterpenic alcohols, tocopherols and sterols.

ACTIVITY 2. SELECTION OF VOLUNTEERS AND ADMINISTRATION OF THE EXPERIMENTAL OILS

Sub-activity 2.1. Selection of volunteers

The postprandial trial will be performed following the fundamental principles of the Declaration of Helsinki, the Council of Europe Convention and the UNESCO Universal Declaration and will take place in the Neurology Department of the Hospital Virgen de Valme in Seville. Adult volunteers will be selected from those that have been diagnosed with Alzheimer\'s disease, based on the results of clinical and cognitive tests using standard criteria as well as with the use of specific biomarkers. Inclusion criteria will also include adequate visual and hearing abilities and to have a follow-up record of the evolution of the disease by healthcare personnel. Exclusion criteria will include clinically significant psychiatric disorders; systemic disease or infection that could affect safety; cardiovascular disease within the last 2 years; uncontrolled hypertension within the last 6 months; cancer within the last 5 years; drug or alcohol abuse within the last 2 years; and insulin-dependent diabetes.

For participation, individuals are also required to give written consent to a protocol approved by the Ethics Committee of Virgen de Valme Hospital, after being informed both orally and writing. They will be encouraged to avoid the consumption of alcoholic beverages and tobacco during the day preceding the execution of the trials.

Sub-activity 2.2. Determination of sample size. The quantitative variable to be examined in this study is the postprandial plasma triglyceride concentration. Assuming that the triglyceride concentration will be reduced by at least 10 % as a consequence of olive pomace oil intake compared to high-oleic sunflower oil and considering a study safety of 95 % (risk α 0.05; zα 1.645) and a power of 90 % (zβ 1.282), a sample size of 16 volunteers is obtained. Due to possible volunteer refusals (although no adverse effects are expected), it is considered prudent to increase the sample size to 20 subjects per group.

Sub-activity 2.3. Administration of experimental meals On the day of the trial, and after 12 hours of overnight fasting, each participant will have a blood sample taken by puncture of the cubital vein. They will then receive a dose of pomace olive oil or high-oleic sunflower oil, which they will eat as part of a breakfast including coffee or milk and toast with wholemeal bread. Following ingestion, each participant will have blood aliquots drawn every hour for a postprandial period of 7 hours. During this time, free access to water intake will be allowed.

ACTIVITY 3. ISOLATION AND CHARACTERISATION OF HUMAN TRIGLYCERIDE-RICH LIPOPROTEINS (TRL)

Sub-activity 3.1. Determinations in blood serum From the aliquots of cubital blood obtained, serum shall be obtained by centrifugation and NaN3, PMSF and aprotinin shall be added as preservatives to avoid proteolytic degradation. The sera will be stored at -80 °C until analysis. In blood serum, triglyceride concentration will be determined by spectrophotometry and apolipoprotein B concentration by immunoturbidimetry. These measurements will allow monitoring of the evolution of postprandial TRL formation and clearance. In addition, serum concentrations of oleanolic acid, alpha-tocopherol and beta-sitosterol will be determined. An analytical extraction and fractionation system will be followed, using the GC-MS method developed in our laboratory for the identification-quantification of the triterpene.

Sub-activity 3.2. Isolation and characterisation of triglyceride-rich lipoproteins (TRL) The presence of oleanolic acid in TRL isolated by ultracentrifugation of sera obtained in the postprandial assay will be investigated. Fatty acid and TG content and apo B48 and B100, as markers for the presence of chylomicrons and VLDL, will be determined by ELISA. These same particles will be used for the microglial activation study (Activity 4).

ACTIVITY 4. MICROGLIAL ACTIVATION IN HUMAN TRL-TREATED BV-2 CELLS In this activity, the mouse cell line BV-2 will be used as a microglial cell model. This cell type will be cultured in DMEM medium supplemented with 10% heat-inactivated FBS, streptomycin (100 mg/ml), and penicillin (100 IU/ml), under 100% humidity and 5% CO2. Experiments will be performed in 5% FBS reduced medium. Cells will be treated with TRLs obtained in the postprandial assay. Treatments will be maintained for 24h.

Sub-activity 4.1. Effect of human TRL on cell viability First, cell viability shall be measured by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium) method. After incubation for 24 h, the cells shall be washed with fresh medium supplemented with 5% FBS and treated with TRL for 12, 24 and 36 h. The cells shall be washed with fresh medium supplemented with 5% FBS and treated with TRL for 12, 24 and 36 h. The MTT solution shall then be added. The resulting formazan precipitate will be dissolved in DMSO and cell viability will be quantified by measuring absorbance at 490 nm.

Sub-activity 4.2. Effect on ROS production and redox activity The fluorescent probe 2',7'-dichlorofluorescein-diacetate (DCFH-DA), which diffuses across the cell membrane and is hydrolysed by intracellular esterases to form non-fluorescent DCFH, will be used to determine the intracellular concentration of ROS. In the presence of ROS, DCFH is rapidly oxidised to form highly fluorescent dichlorofluorescein (DCF). The intensity of the emitted fluorescence (485 nm excitation, 825 nm emission) is proportional to the intracellular concentration of ROS.

Total glutathione as well as oxidised glutathione will be determined by the enzymatic method, based on the NADPH-dependent GSSG reductase activity, which spectrophotometrically monitors the complex formed by GSH and dithionitrobenzoic acid (DTNB).

Sub-activity 4.3. Effect of human TRLs on cytokine production BV-2 cells will be treated with postprandial TRLs and the production of pro-inflammatory and anti-inflammatory cytokines in the culture supernatant will be determined using commercial ELISA kits according to the manufacturer's protocols.

Sub-activity 4.4. Effect of human TRLs on cytokine gene expression BV-2 cells will be treated with postprandial TRLs and mRNA will be isolated. To determine the gene expression of the cytokines of interest, the real-time PCR technique after retrotranscription to cDNA will be used, using primers designed for this purpose.

03

Conditions studied

  • Alzheimer's Disease

Keywords

  • alzheimer's
  • inflammation
  • postprandial
  • pomace olive oil
  • lipoproteins
  • bioactive compounds
  • microglia
  • triglycerides
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of Alzheimer's disease.
  • Adequate visual and hearing abilities.
  • Able to consume breakfast without help.

Exclusion criteria

Exclusion Criteria:

  • psychiatric disorders.
  • Systemic disease or infection that could affect safety.
  • Cardiovascular disease within the last 2 years.
  • Uncontrolled hypertension within the last 6 months.
  • Cancer within the last 5 years.
  • Drug or alcohol abuse within the last 2 years.
  • Insulin-dependent diabetes.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Pomace olive oil group

    The arm receives a breakfast with pomace olive oil as main fat source.

    Dietary Supplement: Consumption of olive pomace olive oil by alzheimer's patients · Dietary Supplement: Consumption of high-oleic sunflower oil by alzheimer's patients

  • Active comparator
    High-oleic sunflower oil group

    The arm receives a breakfast with high-oleic sunflower oil as main fat source.

    Dietary Supplement: Consumption of olive pomace olive oil by alzheimer's patients · Dietary Supplement: Consumption of high-oleic sunflower oil by alzheimer's patients

Interventions

  • Dietary supplementConsumption of olive pomace olive oil by alzheimer's patients

    Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.

  • Dietary supplementConsumption of high-oleic sunflower oil by alzheimer's patients

    Consumption of high-oleic sunflower oil by alzheimer's patients Consumption of olive pomace olive oil by alzheimer's patients as part of a breakfast containing 3 bread slices and coffee with or without skimmed milk.

06

What researchers measure

Primary outcomes

  1. Postprandial serum triglycerides

    Time frame: 6 hours postprandially

Secondary outcomes

  1. Apolipoprotein B-48

    Time frame: 6 hours postprandially

  2. Oleanolic acid

    Time frame: 6 hours postprandially

  3. Alpha-tocopherol

    Alpha-tocopherol in serum

    Time frame: 6 hours postprandially

  4. Beta-sitosterol

    Beta-sitosterol in serum

    Time frame: 6 hours postprandially

  5. Apolipoprotein B-100

    Time frame: 6 hours postprandially

07

Study locations

1 site
08

References and documents

Publications

  • Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007 Jul;3(3):186-91. doi: 10.1016/j.jalz.2007.04.381. PubMed 19595937 ↗
  • Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011 Nov 3;12(12):723-38. doi: 10.1038/nrn3114. PubMed 22048062 ↗
  • Liu B, Hong JS. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J Pharmacol Exp Ther. 2003 Jan;304(1):1-7. doi: 10.1124/jpet.102.035048. PubMed 12490568 ↗
  • McGeer EG, McGeer PL. The role of the immune system in neurodegenerative disorders. Mov Disord. 1997 Nov;12(6):855-8. doi: 10.1002/mds.870120604. No abstract available. PubMed 9399206 ↗
  • McGeer PL, Itagaki S, Tago H, McGeer EG. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Lett. 1987 Aug 18;79(1-2):195-200. doi: 10.1016/0304-3940(87)90696-3. PubMed 3670729 ↗
  • Galloway S, Jian L, Johnsen R, Chew S, Mamo JC. beta-amyloid or its precursor protein is found in epithelial cells of the small intestine and is stimulated by high-fat feeding. J Nutr Biochem. 2007 Apr;18(4):279-84. doi: 10.1016/j.jnutbio.2006.07.003. Epub 2006 Sep 7. PubMed 16962759 ↗
  • Roher AE, Esh CL, Kokjohn TA, Castano EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, Emmerling MR, Soares H, Quinn JF, Kaye J, Connor DJ, Silverberg NB, Adler CH, Seward JD, Beach TG, Sabbagh MN. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement. 2009 Jan;5(1):18-29. doi: 10.1016/j.jalz.2008.10.004. PubMed 19118806 ↗
  • Smith D, Watts GF, Dane-Stewart C, Mamo JC. Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. Eur J Clin Invest. 1999 Mar;29(3):204-9. doi: 10.1046/j.1365-2362.1999.00431.x. PubMed 10202376 ↗
  • Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 2001 Jun 16;322(7300):1447-51. doi: 10.1136/bmj.322.7300.1447. PubMed 11408299 ↗
  • Pallebage-Gamarallage MM, Lam V, Takechi R, Galloway S, Mamo JC. A diet enriched in docosahexanoic Acid exacerbates brain parenchymal extravasation of apo B lipoproteins induced by chronic ingestion of saturated fats. Int J Vasc Med. 2012;2012:647689. doi: 10.1155/2012/647689. Epub 2011 Nov 10. PubMed 22121489 ↗
  • Grant WB. Dietary links to Alzheimer's disease: 1999 update. J Alzheimers Dis. 1999 Nov;1(4-5):197-201. doi: 10.3233/jad-1999-14-501. PubMed 12214118 ↗
  • Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol. 1997 Nov;42(5):776-82. doi: 10.1002/ana.410420514. PubMed 9392577 ↗
  • Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, Schneider J, Wilson RS. Dietary fats and the risk of incident Alzheimer disease. Arch Neurol. 2003 Feb;60(2):194-200. doi: 10.1001/archneur.60.2.194. PubMed 12580703 ↗
  • Castellano JM, Garcia-Rodriguez S, Espinosa JM, Millan-Linares MC, Rada M, Perona JS. Oleanolic Acid Exerts a Neuroprotective Effect Against Microglial Cell Activation by Modulating Cytokine Release and Antioxidant Defense Systems. Biomolecules. 2019 Nov 1;9(11):683. doi: 10.3390/biom9110683. PubMed 31683841 ↗
  • Espinosa JM, Castellano JM, Garcia-Rodriguez S, Quintero-Florez A, Carrasquilla N, Perona JS. Lipophilic Bioactive Compounds Transported in Triglyceride-Rich Lipoproteins Modulate Microglial Inflammatory Response. Int J Mol Sci. 2022 Jul 12;23(14):7706. doi: 10.3390/ijms23147706. PubMed 35887052 ↗
  • Espinosa JM, Quintero-Florez A, Carrasquilla N, Montero E, Rodriguez-Rodriguez A, Castellano JM, Perona JS. Bioactive compounds in pomace olive oil modulate the inflammatory response elicited by postprandial triglyceride-rich lipoproteins in BV-2 cells. Food Funct. 2023 Oct 2;14(19):8987-8999. doi: 10.1039/d3fo02460a. PubMed 37740318 ↗

Individual participant data

Plan to share: No — Data will be stores under the supervision of the PI and will be shared only with personnel of the research team.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 31 months is close to that.

Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion May 2026 → Dec 2026 and completion Jun 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2024
First posted
Feb 7, 2024
StartActual
May 1, 2024
Primary completionEst.
Dec 30, 2026was May 2026
CompletionEst.
Jun 30, 2027was Jun 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Hospital Virgen de Valme · Seville, Spain
Show 1 removed
  • Hospital Virgen de Valme · Seville, Spain
Nov 18, 2026
Primary completion
May 30, 2026→Dec 30, 2026
Nov 18, 2026
Study completion
Jun 30, 2026→Jun 30, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    1 site added, 1 site removed
    Show site
    • Hospital Virgen de Valme · Seville, Spain
    Show 1 removed
    • Hospital Virgen de Valme · Seville, Spain
    Primary completion May 30, 2026→Dec 30, 2026
    Study completion Jun 30, 2026→Jun 30, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06245616
Lead sponsor
Spanish National Research Council
Responsible party
Javier Sanchez Perona (Principal Investigator, Spanish National Research Council) — Principal investigator
First posted
Feb 7, 2024
Start date
May 1, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion